Page 359 - The Vasculitides, Volume 1: General Considerations and Systemic Vasculitis

Giant Cell Arteritis 333

[134] Bongartz T, Matteson EL. Large-vessel involvement in giant cell arteritis. Curr. Opin.
Rheumatol., 2006; 18:10-17.

[135] González-Gay A, Blanco R, Rodríguez-Valverde V, et al. Permanent visual loss and
cerebrovascular accidents in giant cell arteritis: Predictors and response to treatment.
Arthritis Rheum., 1998; 41: 1497–1504.

[136] Allison MC, Gallagher PJ. Temporal artery biopsy and corticosteroid treatment. Annals
of the Rheumatic Diseases, 1984; 43:416-417.

[137] Achkar AA, Lie JT, Hunder GG, et al. How does previous glucocorticosteroid
treatment affect the biopsy findings in giant cell (temporal) arteritis? Ann. Intern. Med.,
1994; 120:987-992.

[138] Bury D, Joseph J, Dawson T. Does preoperative steroid treatment affect the histology in
giant cell (cranial) arteritis? J. Clin. Pathol., 2012; 65:1138-1140.

[139] Hall S, Persellin S, Lie JT, et al. The therapeutic impact of temporal artery biopsy.
Lancet, 1983; 2:1217.

[140] Murchison AP, Gilbert ME, Jurij R, et al. Validity of the American College of
Rheumatology Criteria for the Diagnosis of Giant Cell Arteritis, Am. J. Ophthalmol.,
2012;154:722-729.

[141] Hunder GG, Sheps SG, Allen GL, et al. Daily and alternate-day corticosteroid regimens
in treatment of giant cell arteritis: comparison in a prospective study. Ann. Intern. Med.,
1975; 82:613-618.

[142] Proven A, Gabriel SE, Orces C, et al. Glucocorticoid therapy in giant cell arteritis:
duration and adverse outcomes. Arthritis Rheum., 2003; 49:703-708.

[143] Danesh-Meyer H, Savino PJ, et al. Poor prognosis of visual outcome after visual loss
from giant cell arteritis. Ophthalmology, 2005; 112:1098-1103.

[144] Aiello PD, Trautman JC, McPhee TJ, et al. Visual prognosis in giant cell arteritis.
Ophthalmology, 1993; 100:550-555.

[145] Kyle V, Hazleman BL. Treatment of polymyalgia rheumatica and giant cell arteritis. I.
Steroid regimes in the first two months. Annals Rheum. Dis., 1989; 48:658-661.

[146] Lundberg I, Hedfors E. Restricted dose and duration of corticosteroid treatment in
patients with polymyalgia rheumatica and temporal arteritis. J. Rheumatol., 1990:
17:1340-1345.

[147] Ferris J, Lamb R. Polymyalgia rheumatica and giant cell arteritis. BMJ 1995; 311:455.
[148] Chevalet P, Barrier JH, Pottier P, et al. A randomized, multicenter, controlled trial using

intravenous pulses of methylprednisolone in the initial treatment of simple forms of
giant cell arteritis: a one year followup study of 164 patients. J. Rheumatol., 2000;
27:1484-1491.
[149] Mazlumzadeh M, Hunder GG, Easley KA, et al. Treatment of giant cell arteritis using
induction therapy with high-dose glucocorticoids : a double-blind, placebo-controlled,
randomized prospective clinical trial. Arthritis Rheum., 2006; 54:3310-3318.
[150] Kyle V 1990. Stopping steroids in polymyalgia rheumatica and giant cell arteritis.
Treatment usually lasts for two to five years. BMJ, 1990; 300:344.
[151] Narvaez J, Nolla-Sole JM, Clavaguera MT, et al Longterm therapy in polymyalgia
rheumatica: Effect of coexistent temporal arteritis. J. Rheumatol., 1999; 26:1945-1952.
[152] Mahr AD, Jover JA, Spiera RF, et al. Adjunctive methotrexate for treatment of giant
cell arteritis. An individual patient data meta-analysis. Arthritis Rheum, 2007; 56:2789-
97.

Complimentary Contributor Copy